Definition, Diagnosis, Risk Stratification and Management of Newly Diagnosed Multiple Myeloma: The Saudi Myeloma Working Group Guidelines.

IF 2.7 4区 医学 Q2 HEMATOLOGY
Ghazi S Alotaibi, Abdullah S Al Saleh, Ayman Alhejazi, Majed Alahmadi, Ibraheem Motabi, Fahad Z Alsharif, Abdullah Alamer, Omar Abduljalil, Imran Tailor, Mohammed Marei, Ahmed S Barefah, Mansour Aljabry, Saud Alhayli, Binyam Usman, Amr Hanbali, Amal Alabdulwahab, Ihab ElHemaidi, Hatem Mahmoud Alahwal, Enas Mutahar, Ahmad Alsaeed
{"title":"Definition, Diagnosis, Risk Stratification and Management of Newly Diagnosed Multiple Myeloma: The Saudi Myeloma Working Group Guidelines.","authors":"Ghazi S Alotaibi, Abdullah S Al Saleh, Ayman Alhejazi, Majed Alahmadi, Ibraheem Motabi, Fahad Z Alsharif, Abdullah Alamer, Omar Abduljalil, Imran Tailor, Mohammed Marei, Ahmed S Barefah, Mansour Aljabry, Saud Alhayli, Binyam Usman, Amr Hanbali, Amal Alabdulwahab, Ihab ElHemaidi, Hatem Mahmoud Alahwal, Enas Mutahar, Ahmad Alsaeed","doi":"10.1016/j.clml.2025.06.005","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple myeloma is a rising concern globally, with increasing incidence and mortality, especially in low- and middle-income countries. In Saudi Arabia, multiple myeloma care faces significant challenges outside tertiary care centers, including delays in diagnosis, limited availability of standardized treatment protocols, and considerable disparities in healthcare infrastructure. These issues are particularly prominent in non-urban and secondary healthcare facilities, where access to specialized diagnostics and therapies may be restricted, impacting early detection and optimal management of the disease. Although treatment advances have improved survival rates, multiple myeloma remains incurable and poses significant financial burdens due to the high cost of therapies, particularly in resource-constrained settings. This updated guideline from the Saudi Myeloma Working Group aims to address the gaps in newly diagnosed multiple myeloma management in Saudi Arabia.xsy.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clml.2025.06.005","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Multiple myeloma is a rising concern globally, with increasing incidence and mortality, especially in low- and middle-income countries. In Saudi Arabia, multiple myeloma care faces significant challenges outside tertiary care centers, including delays in diagnosis, limited availability of standardized treatment protocols, and considerable disparities in healthcare infrastructure. These issues are particularly prominent in non-urban and secondary healthcare facilities, where access to specialized diagnostics and therapies may be restricted, impacting early detection and optimal management of the disease. Although treatment advances have improved survival rates, multiple myeloma remains incurable and poses significant financial burdens due to the high cost of therapies, particularly in resource-constrained settings. This updated guideline from the Saudi Myeloma Working Group aims to address the gaps in newly diagnosed multiple myeloma management in Saudi Arabia.xsy.

新诊断多发性骨髓瘤的定义、诊断、风险分层和管理:沙特骨髓瘤工作组指南。
多发性骨髓瘤是全球日益关注的问题,发病率和死亡率不断上升,特别是在低收入和中等收入国家。在沙特阿拉伯,多发性骨髓瘤的治疗面临着三级医疗中心之外的重大挑战,包括诊断延误、标准化治疗方案的有限可用性以及医疗基础设施的巨大差异。这些问题在非城市和二级保健设施中尤为突出,在这些设施中,获得专门诊断和治疗的机会可能受到限制,影响到疾病的早期发现和最佳管理。尽管治疗进步提高了生存率,但多发性骨髓瘤仍然无法治愈,并且由于治疗费用高,特别是在资源有限的环境中,造成了巨大的经济负担。这份来自沙特骨髓瘤工作组的更新指南旨在解决沙特阿拉伯新诊断的多发性骨髓瘤管理方面的差距。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.70
自引率
3.70%
发文量
1606
审稿时长
26 days
期刊介绍: Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信